Retatrutide and BPC-157 Together: What Is Known
Retatrutide and BPC-157 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 2 results, 2 Oct 2026).
Side by side
Showing 12 of 13 fields where the two differ. WADA are the same or both unknown.
| Field | Retatrutide | BPC-157 |
|---|---|---|
| Class | GLP-1 / GIP / glucagon triple agonist | Gastric pentadecapeptide |
| Also called | reta, GLP-3, LY3437943 | BPC, body protection compound, Pentadecapeptide BPC 157 |
| Category | GLP-1 & metabolic | Healing & recovery |
| FDA status | Investigational · phase 3 | PCAC voted 8–6 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized |
| WADA | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 |
| Human studies we summarised | 11 human (11 randomized or controlled) of 16 summarised | 3 human (0 randomized or controlled) of 25 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg | 2 mg, 5 mg, 10 mg, 20 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Not in the letters we track |
Retatrutide: liver fat and body composition
In a phase 2 substudy at 24 weeks, relative liver fat changed by -81.4% on 8 mg and -82.4% on 12 mg of retatrutide, versus +0.3% on placebo.[18]
In a body-composition substudy in type 2 diabetes, total fat mass fell 26.1% with pooled retatrutide 8 mg versus 4.5% with placebo.[9]
BPC-157 evidence
In rats, BPC 157 improved ligament healing. This is animal evidence only.[19]
A sports-medicine review notes that BPC-157 lacks US FDA approval and that its use is banned in professional sports.[20]
Adverse events reported for retatrutide
In the phase 2 obesity trial, heart-rate increases were dose-dependent, peaked at 24 weeks and declined afterwards.[21]
Together
The retatrutide with BPC-157 search returned 2 PubMed records, none classed as a study of the pair.
Calculated from pubmed query ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab]); search date 2026-10-02; records returned 2; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key bpc-157__retatrutide); no arithmetic applied.
WADA's S0 class lists BPC-157 by name among non-approved substances.[6]
Common questions
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 8Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 9Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 10Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 11Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 12Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 13Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 14Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 15Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 18Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nature medicine · 2024PMID 38858523Accessed 2 Oct 2026
- 19Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2010PMID 20225319Accessed 2 Oct 2026
- 20Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 21Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 22Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.